PIK3CB and ovarian clear cell cancer: Thus, MTC-22 could be used to investigate mechanisms underlying ovarian clear cell carcinoma, particularly cases with PIK3CB mutations, or to validate new diagnostic and therapeutic approaches for this type of cancer.